Christa Dang

Nov 7, 2024 | medrxiv.org | Matthew Kang |Dhamidhu Eratne |Samantha M. Loi |Christa Dang

HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon,...

Oct 6, 2024 | alz-journals.onlinelibrary.wiley.com | Dhamidhu Eratne |Courtney Lewis |Christa Dang |Charles B. Malpas

1 INTRODUCTION Despite major improvements in clinical assessment, many patients with neurodegenerative disorders (ND) still face significant barriers and challenges to timely, accurate diagnosis; delays often last several years even with gold-standard assessments.1 These challenges are worse for younger people (onset of symptoms < 60–65 years of age), where a wider range of ND and less typical presentations of ND are more common, and substantial overlap in symptoms with psychiatric disorders...